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Abstract: Enantioselective syntheses from dimethyl tartrate of 1,3,5-triazine homo-N-
nucleoside analogs, containing a 1,4-dioxane moiety replacing the sugar unit in natural 
nucleosides, were accomplished. The triazine heterocycle in the nucleoside analogs was 
further substituted with combinations of NH2, OH and Cl in the 2,4-triazine positions. 
Keywords: 1,3,5-Triazine; 1,4-Dioxane; Nucleoside analogue; Heterocycle; Homo-N-
nucleoside; Nucleoside analogs. 
 
 
Introduction 
 
Nucleoside analogs represent a potentially important class of medicinal active agents that have 
found uses in antitumor and antiviral drugs [1]. However, some drugs such as AZT [2-3], ddI [3], 3TC 
[4], are rapidly becoming less effective due to the developing drug resistance. Multi-drug resistance is 
a serious problem also for chemo- and anticancer therapy. In addition some drugs exhibit a variety of 
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side effects. Therefore, it is desirable to develop new, active nucleoside analogs for application in 
medicine. 
It is interesting to note that purines, amino derivatives of 1,3,5-triazines (also named s-triazines) 
and substituted guanines were found in the Orgueil meteorite [5-6]. The presence of s-triazines was 
interesting, since the various 1,3,5-triazines can be formed from hydrogen cyanide, ammonia and 
water, components believed to be plentiful in the primordial soup. Triazines may therefore have been 
abundant on early Earth [7]. The interesting question therefore arises as to what extend these triazines 
have played a role in the evolution of the original RNA [8].  
The 1,3,5-triazine heterocyclic system is today found in a number of bioactive molecules such as 
herbicides and pharmaceutical products [9]. Various triazine substituted molecules exhibit diverse 
biological activities, having thus been reported as potentially cardiotonic [10-11], anti-HIV [12-13], 
antitumor [14] and anticancer agents [15]. Some triazines have found clinical applications. 
Hexamethylmelamine (HMM) has for example been used as antitumor agents [16]. Therefore 
nucleoside analogues containing triazines as the nucleic base equivalents are interesting subjects to 
study [17-18]. 
In the solid state 2-amino-4,6-dichloro-1,3,5-triazine form a ribbon structure of hydrogen bonded 
dimers[19]. Triazine oligomers were shown to self-assemble in duplex-strand structures [20]. Amino 
substituted triazine based oligomers and cyclic receptor molecules have also been studied [21]. Like 
the natural complementary pyrimidine and purine nucleic bases forming associates through hydrogen 
bonds as observed in the nucleic acid structures, amino and hydroxyl substituted triazines can self-
assemble into supramolecular structures through the formation of hydrogen bonds [22-23]. A typical 
example of such associates is sketched in Figure 1. In addition, it has been observed that triazine 
derivatives, for example 2,6-diamino-1,3,5-triazines, may function as purine mimics and can recognize 
pyrimidines, forming associates with for example uracils or thymines through hydrogen bonding [24-
26], Figure 2. 
 
Figure 1. Interaction between NH2 and OH substituted triazines. 
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Figure 2. Interaction between triazine and uracil structures. 
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Monoaminotriazine nucleoside analogs also represent interesting structures, as they may mimic 
adenines, forming associates with uracil analogs, Figure 3. 
 
Figure 3. Interaction between nucleic bases (adenine-uracil) and monoaminotriazine 
derivatives with uracil. 
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These observations suggest the use of triazine nucleoside analogs as leads for the development of 
new nucleoside and nucleotide analogs for medicinal application. Considering the potential 
applications of the 1,3,5-triazine based systems, surprisingly few triazine nucleoside analogs or 
triazine glycosides have been reported in the literature [27-31]. For these reasons we found it viable to 
initial a study of the synthesis of triazine based nucleoside analogs.  
 
Results and Discussion 
 
Rather than applying the five-membered sugars found in the natural nucleosides, we targeted on the 
application of the more robust and more flexible sugar analogs containing the 1,4-dioxane moiety, for 
example compound 1, whose synthesis has been reported in a previous publication [32]. Compound 1, 
containing an unnatural sugar analog may also prove to be robust in biologic systems, as enzymes may 
not find pathways to convert the unnatural nucleoside system. The synthesis of the triazine O-
nucleoside analogs 2, in which a 1,4-dioxane sugar moiety was connected to a dichloro substituted 
triazine ring system via an ether linkage at the anomeric position (Figure 4) was thus the initial 
synthetic goal.  
Figure 4. Triazine nucleoside analogs. 
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Preparation of this structure was attempted from the 1,4-dioxane sugar analog 1, by its reaction with 
2,4,6-trichloritriazine. However, all attempts failed to give the desired product, as formation of the 
elimination product 3 always predominated (Scheme 1). This was surprising, as triazine glycosides are 
known [30]. However, in the 1,4-dioxane system, the CH2-group neighboring the anomeric -OH group 
may here actually facilitate an elimination reaction pathway, providing instead product 3, which was 
Molecules 2008, 13              
 
 
3095
isolated and the structure confirmed by NMR spectroscopy. As a spin-off of this observation, we are 
currently exploring the possible use of chlorotriazine as an elimination reagent for the formation of 
alkenes from alcohols. 
 
Scheme 1. Reaction of 1,4-dioxane sugar analog 1 with 2,4,6-trichlorotriazine. 
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The observed instability of the triazine O-nucleoside analog 2 (Scheme 1), prompted us to design 
the potentially more stable triazine homo-N-nucleoside analogs, 4 (Figure 5). N-glycosidic nucleoside 
analogs represent a known, well established class of stable modified nucleosides [33-37]. For increased 
stability, the linking ether group was thus replaced by the corresponding –CH2-NH- linker. This was 
expected to result in a conformationally more flexible but also a chemically and biologically more 
stable structure. Hence, the alternative structures 4, became the new targets. Nucleophilic, aromatic 
substitution readily takes place with chlorosubstituted triazines. Therefore, we could conveniently 
adopt a general synthetic procedure in which variously substituted chlorotriazines were reacted with 
for example the amino sugar analogues 5 (Scheme 2). 
 
 Figure 5. Structure of triazine homo-N-nucleoside analogs. 
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For the purpose of constructing triazine nucleoside analogs that may function as complementary 
bases to the naturally occurring bases, controlled substitution in the 2- and 4-positions of the triazine 
heterocyclic system was investigated. Thus, the triazine may be substituted with various combinations 
of H, OH and NH2 groups. The combinations that included H were not prepared, but instead chloro 
substituted triazines were used. Chloro-substituted purine and pyrimidine systems have also found uses 
in medicinal chemistry. The OH- / NH2 substituted triazine may correspond to the nucleobases 
Molecules 2008, 13              
 
 
3096
cytosine and guanine, while the OH / OH combination corresponds to uracil and thymine. It has 
previously been reported that such triazine systems may form hydrogen bond with the complementary 
natural bases [38]. 
The enantiomerically pure homo amino sugar analogs 5a and 5b were readily prepared from iodides 
6a and 6b by the reaction with sodium azide in DMF [39-40], to give azides 7a and 7b in 76  and 82 % 
yields, respectively. Subsequent hydrogenolysis of the azides using Pd-C as the catalyst readily 
provided the corresponding amines 5a and 5b, respectively, in essentially quantitative yields. Iodides 6 
were obtained from (2R,3R)-dimethyl tartrate as previously reported [41] according to the reaction 
sequence shown in Scheme 2. Product 6 was isolated as an approximately 1:1 diastereomeric mixture 
of trans-6a and cis-6b. The application of the tartrates as starting materials, readily available from the 
chiral pool, conveniently allow for the synthesis of all the possible stereoisomers of the target 
molecules. 
 
Scheme 2. Synthesis of homo amino-1,4-dioxane pseudo-sugar 5a and 5b. 
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Structures 6a and 6b were established by NMR spectroscopy. Thus, product 6a exhibited a large H-
2/H-3 coupling constant (10.2 Hz), which was in agreement with an axial H-2 proton. The 
corresponding coupling constant (3.6 Hz) observed for compound 6b was in agreement with the 
corresponding cis-isomer configuration (Figure 6).  
 
Figure 6. Molecular structures 6a and 6b. 
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The 3,5-diaminotriazine homo-N-nucleoside analogs 8a and 8b were prepared by the reaction of the 
amino sugar analogs 5a and 5b respectively with 2-chloro-4,6-diaminotriazine in DMF in the presence 
of triethylamine. Thus, trans-amine 5a afforded the desired diamino triazine homo-N-nucleoside 
analog 8a in 39 % yield. The corresponding cis-triazine homo-N-nucleoside 8b was obtained in 50 % 
isolated yield (Scheme 3). 
 
Scheme 3. Synthesis of diaminotriazine homo-N-nucleoside analogues 8a and 8b. 
 
        
5a  trans
5b  cis
O O
O
H3C
H3C
O
CH2NH2
       
8a trans, 39 %
8b  cis, 50 %
O O
O
H3C
H3C
O
CH2NH+
N
N
N
NH2
NH2
Cl
Et3N N
N
N
NH2
NH2
DMF
 
 
For the purpose of mimicking the thymine and uracil bases, the 2,4-dihydroxy substituted triazine 
systems were also prepared. The 2-chloro-4,6-dihydroxy-1,3,5-triazine was readily prepared according 
to a known procedure [42] from commercial available 2,4,6-trichlorotriazine by treatment in an 
aqueous sodium hydroxide solution. This provided the monosodium salt of 2-chloro-4,6-dihydroxy-
1,3,5-triazine 9, which was further coupled with 5a in DMF in the presence of triethylamine to provide 
triazine nucleoside analogue 10a in 58 % isolated yield. The cis- triazine nucleoside analogue 10b was 
similarly prepared from 5b in 55 % isolated yield (Scheme 4). 
 
Scheme 4. Synthesis of triazine homo-N-nucleoside analogue 10a and 10b. 
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Monoaminotriazine nucleoside analogues were also of interest, as they may mimic adenines, 
forming associates with for example uracil analogs (Figure 3). Thus for further structural variations of 
the triazine N-nucleoside analogs, 5a and 5b, respectively, were coupled with 2,4-dichloro-6-
aminotriazine (11), which was obtained from 2,4,6-trichlorotriazine by treatment with ammonia at 0 oC 
[43]. Products 12a and 12b were obtained in 88 % and 77 % isolated yields (Scheme 5). 
Interestingly, a chromatographically pure sample of 12a was observed to exhibit an exchange 
effects in the 1H-NMR spectra. When the 1H-NMR of 12a was recorded at 25 oC in CDCl3, the spectra 
exhibited the presence of two series of signals ascribed to two different structures in a 5:8 ratio. 
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However, these signals collapsed into a single set of signals when the temperature of the sample 
exceeded 50 oC. In the course of this process, the chemical shifts also changed. Product 12b exhibited 
a similar behavior. 
 
Scheme 5. Synthesis 2-chloro-4-amino triazine homo-N-nucleoside analogues 12a and 12b. 
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The observed temperature effects on the NMR spectra of 12 is not yet clear, but may be rationalized 
in terms of dimerization of 12 or due to the presence of rotamers. Aminotriazines may form complexes 
through hydrogen bond formation. In this respect it is also worthwhile to note that a number of 
possible tautomers of the aminotriazine system may play a role in for example dimer formation. 
Triazine systems have been observed to exhibit rotational isomerism [44-47]. For the present system, 
12, there are several rotatable bonds. One of these, the triazine-NH bond, may be associated with a 
high rotational barrier, for example due to a possible, partial C-N double bond character, as the result 
of tautomer formation. An initial, though rudimentary conformational analysis, using theoretical 
molecular mechanics calculations (ChemModel/MMX), indicated the presence of rotamers and several 
low-energy conformations. Due to a number of possible rotatable bonds and the dimensional 
limitations associated with the applied method, we can not here point to distinct structures related to 
the transformations observed in the NMR experiments. These aspects of the properties of products 12a 
and 12b have so far not been further pursued. 
 
Conclusions 
 
In conclusion, optically active homo-N-nucleoside analogs containing a 1,3,5-triazine base 
equivalent, were synthesized from dimethyl tartrate. The triazines, including the 2,4-diamino 
substituted, the dihydroxy substituted and chloro-amino 2,4-disubstituted triazines, were linked to the 
homo-1,4-dioxoane sugar analog moiety via a CH2NH linker. Biologic screening of the prepared 
nucleoside analogs is now in progress. 
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Experimental 
 
General 
 
NMR spectra were recorded on Bruker Avance DPX 400 instruments. Chemical shifts are reported 
in ppm using TMS as the internal standard in CDCl3 or relative to 2.50 ppm for 1H and 39.99 ppm for 
13C in DMSO-d6 or 3.31 ppm for 1H and 49.15 ppm for 13C in CD3OD. Structural assignments were 
based on 1H, 13C, DEPT135 and 2D spetra, COSY, HSQC, HMBC, NOESY. EI-Mass and ESI spectra 
were recorded on a Finnigan MAT 95XL spectrometer. IR spectra of the solid products were obtained 
on a Thermo Nicolet FT-IR Nexus spectrometer equipped with a Smart Endurance reflection cell. 
Silica gel Kieselgel 60G (Merck) was used for Flash Chromatography. The solvents were purified by 
standard methods. The preparations of 6a and 6b were described in the previous paper [41]. 
 
(5S)-5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-6-dihydro-1,4-dioxane (3). To compound 1 (0.66 g, 3.2 
mmol) in dry THF (12 mL) was added sodium hydride (101 mg, 4.2 mmol) and the mixture was stirred 
for 10 min. at room temperature. 2,4,6-Trichloro-1,3,5-triazine (0.80 g, 6.2 mmol) was then added to 
the mixture, which was refluxed for 4 hours. The mixture was concentrated and purified by flash 
chromatography by using a mixture of diethyl ether and n-hexane (1:3) as eluent to provide product 3 
(0.1 g, 17 %). 1H-NMR (400 MHz, CDCl3) δ 1.38 (d, J = 0.4 Hz, 3H, H-7), 1.45 (d, J = 0.4 Hz, 3H, H-
7), 3.84 (dd, J = 11.2 Hz, 7.2 Hz, 1H, H-3), 3.89 (dd, J = 8.4 Hz, 6.8 Hz, 1H, H-6), 3.96-4.0 (m, 1H, 
H-4), 4.04-4.10 (m, 2H, H-3 and H-6), 4.27 (dt, J = 5.2 Hz, 6.8 Hz, 1H, H-5), 5.99 (d, J = 3.4H, 1H, H-
2), 6.04 (d, J = 3.4 Hz, 1H, H-1) ppm. 13C-NMR (100 MHz, CDCl3) δ 25.3, 26.2, 65.0, 65.3, 73.3, 
74.3, 109.9, 126.5, 126.8 ppm. 
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(2S,5S)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]- 5-azidomethyl-1,4-dioxane (7a). To the solution of 
6a (1.30 g, 4 mmol) in DMF, sodium azide (1.41 g, 22 mmol) was added. The mixture was stirred 
overnight at 80 °C. The mixture was concentrated under reduced pressure and the residue was 
extracted with chloroform. The filtrate was concentrated and the residue purified by flash 
chromatography using a mixture of ethyl ether and n-hexane (1:2) as eluent to give product 7a (yield 
0.79, 82 %). 1H-NMR (400 MHz, CDCl3) δ  4.06 (dt, 1H, J = 6.8 Hz, 5.6 Hz, H-8), 3.97 (dd, 1H, J = 
8.4 Hz, 6.0 Hz, H-9 eq), 3.85 (dd, 1H, J = 11.6 Hz, 2.4 Hz, H-3  eq), 3.79 (dd, 1H, J = 8.4 Hz, 7.2 Hz, 
H-9 ax), 3.77 (dd, 1H, J = 11.2 Hz, 2.4 Hz, H-6 eq), 3.76-3.69 (m, 1H, H-2), 3.61 (ddd, 1H, J = 2.0 Hz 
= 5.2 Hz, H-5), 3.53 (dd, 1H, J = 11.2 Hz, 7.6 Hz, H-6 ax), 3.48 (dd, 1H, J = 11.6 Hz, 10.4 Hz, H-3 
ax), 3.26 (d, 2H, J = 5.2 Hz, H-7), 1.43 (d, 3H, J = 0.4 Hz, H-13), 1.36 (d, 3H, J = 0.4 Hz, H-13). 13C-
NMR (100 MHz, CDCl3) δ 109.9, 75.5, 75.1, 74.0, 68.6, 67.5, 65.2, 51.6, 26.4, 25.4. IR (neat): 2984, 
2866, 2096, 1448, 1370, 1292 cm-1. HRMS (m/z, ESI): for C10H17N3O4 [M+Na]+; Calcd. 266.1116; 
Found 266.1108.  
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7a  
(2S,5R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]- 5-azidomethyl-1,4-dioxane (7b). The trans- 
compound 7b was prepared by following the same procedure as described for 7a. Product 7b was 
obtained as a colorless oil (0.73 g, 75.8 %).  1H-NMR (400 MHz, CDCl3) δ 4.34 (dd, 1H, J = 13.6 Hz, 
6.8 Hz, H-8), 4.04 (dd, 1H, J = 8.4 Hz, 6.4 Hz, H-3 eq), 3.82-3.76 (m, 3H, H-2, H-6), 3.75 (dd, 1H, J = 
8.4 Hz, 6.8 Hz, H-3 ax), 3.70 (dd, 1H, J = 6.8 Hz, 12 Hz, H-9 ax), 3.69-3.61 (m, 1H, H-7), 3.66 (dd, 
1H, J = 6.8 Hz, J = 1.6 Hz, H-9 eq), 3.63 (dd, 1H, J = 3.2 Hz, J = 6.4 Hz, H-5), 3.37-3.32 (m, 1 H, H-
7), 1.44 (d, 3H, J = 0.4 Hz, H-13), 1.38 (d, 3H, J = 0.4 Hz, H-13) ppm. 13C-NMR (100 MHz, CDCl3) δ 
110.0, 74.9, 74.0, 71.9, 65.8, 65.3, 63.2, 45.0, 26.6, 25.6 ppm. HRMS (m/z, ESI): for C10H17N3O4 
(M+Na+), Calcd. 266.1116, found 266.1115. 
 
O
O
O
O
N3
1
23
4
5 6
7
8
910
11
1213
13
7b  
(2S,5S)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-5-aminomethyl-1,4-dioxane (5a). To compound 7a 
(90.1 mg, 0.365 mmol) dissolved in MeOH (5 mL) was added Pd-C (5 % Pd, 13.4 mg, 0.2 mol %). 
The suspension was stirred for 2.5 hours under a hydrogen atmosphere (1.8 – 2.0 bar), until TLC 
indicated complete conversion. The catalyst was removed by filtration and the filtrate was 
concentrated to dryness. The resulting residue was dissolved in 1 mL MeOH, and filtered through a 
plug of Celite, which was then washed five times with MeOH (2 Ml). The combined filtrates were 
evaporated to give a colorless oil as product. The yield was 80.4 mg (0.371 mmol, 99 %) product. It 
became solid after standing a couple of days. The 1H-NMR (400 MHz, CDCl3) δ  4.06 (dt, 1H, J = 6.8 
Hz, 6.4 Hz, H-8), 3.97 (dd, 1H, J = 8.4 Hz, 6.8 Hz, H-9eq), 3.85 (dd, 1H, J = 11.6 Hz, 2.4 Hz, H-3 eq), 
3.79 (dd, 1H, 8.0 Hz, 7.2 Hz, H-9 ax), 3.74 (dd, 1H, J = 10.8 Hz, 2.0 Hz, H-6 eq), 3.62-3.55 (m, 2H, 
H-2, H-5), 3.52 (dd, 1H, J = 10.8 Hz, 10.4 Hz, H-6 ax), 3.41 (dd, 1H, J = 11.6 Hz, 10.4 Hz, H-3 ax), 
2.78 (dd, 1H, J = 13.2 Hz, 4.0 Hz, H-7), 2.69 (dd, 1H, J = 13.2 Hz, 8.4 Hz, H-7), 2.57 (broad s, 2H, 
NH2), 1.43 (d, 3H, J = 0.4 Hz, H-13), 1.36 (d, 3H, J = 0.4 Hz, H-13) ppm. 13C-NMR (100 MHz, 
CDCl3) δ 109.7, 75.9, 75.6, 75.2, 69.1, 67.4, 65.2, 42.7, 26.4, 25.4 ppm. HRMS (m/z, ESI): for 
C10H17N3O4 (M+H+), calcd. 218.1392, found 218.1389. 
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(2S,5R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-5-aminomethyl-1,4-dioxane (5b). The cis- compound 
5b was prepared by following the same method as for synthesis of 5a. 1H-NMR (400 MHz, CDCl3) δ 
4.38 (ddd, 1H, J = 6.8 Hz, 6.8 Hz, 6.8 Hz, H-8), 4.04 (dd, 1H, J = 8.4 Hz, 6.8 Hz, H-9 eq), 3.76 (d, 2H, 
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J = 4.4 Hz, H-3), 3.73 (dd, 1H, J = 8.0 Hz, J = 7.2 Hz, H-5), 3.68-3.58 (m, 4 H, H-9 ax, H-6, H-2), 
3.10 (dd, 1H, J = 13.2 Hz, 8.8 Hz, H-7), 2.79 (dd, 1H, J = 13.2 Hz, 4.4 Hz, H-7), 2.42 (bs, 2H, NH2), 
1.44 (d, 3H, J = 0.4 Hz, H-13), 1.38 (d, 3H, J = 0.4 Hz, H-13) ppm. 13C-NMR (100 MHz, CDCl3): δ 
109.8, 74.6, 74.4, 73.9, 65.8, 65.5, 63.2, 41.1, 26.6, 25.5 ppm. IR (neat): 2990, 2864, 1625, 1450, 
1434, 1376, 1367, 1122, 1022, 979 cm-1. HRMS (m/z, ESI): for C10H17N3O4 (M+H+), calcd. 218.1392, 
found 218.1394.  
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2,4-Diamino-6-[[(2S,5S)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,4-dioxan-5-yl]methylamino]-
1,3,5- triazine (8a). To a solution of 5a (244 mg, 1.12 mmol) and triethylamine (0.16 mL, 1.15 mmol) 
in DMF (16 mL) was added 2-chloro-4,6-diaminotriazine (80 mg, 0.55 mmol). The mixture was 
heated at 80 oC and stirred overnight. The solution was evaporated under high vacuum and the residue 
was purified by column chromatography using gradient eluent systems [dichloromethane and methanol 
(20:1); dichloromethane and methanol (10:1)]. Product 8a was obtained as a white solid in 39 % yield. 
1H-NMR (400 MHz, CDCl3) δ 6.40 (t, 1H, J = 6 Hz, NH), 6.06 (s, 2H, NH2), 5.95 (s, 2H, NH2), 3.96-
4.01 (m, 1H, H-8), 3.89 (dd, 1H, J = 8.2 Hz, 6.6 Hz, H-9), 3.79 (dd, 1H, J = 11.6, 2.6 Hz, H-3), 3.72 
(dd, 1H, J = 8.2 Hz, 7.0 Hz, H-9), 3.67 (dd, 1H, J = 11.2 Hz, 2 Hz, H-6), 3.52-3.58 (m, 1H, H-2), 3.44-
3.48 (m, 1H, H-5), 3.30-3.37 (m, 1H, H-6), 3.21-3.29 (m, 2H, H-3, H-7), 3.08-3.15 (m, 1H, H-3), 1.30 
(s, 3H, H-13), 1.24 (s, 3H, H-13) ppm. 13C-NMR (100 MHz, CDCl3) δ 167.0, 166.4, 108.4, 74.5, 73.6, 
69.1, 66.6, 64.3, 41.0, 26.1, 25.3 ppm. IR (neat): 3353, 3130, 2983, 1633, 1608, 1537, 1455, 1108, 
1048 cm-1. HRMS (m/z, ESI): for C13H22N6O4 (M+H+), calcd. 327.1780, found 327.1780. 
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2,4-Diamino-6-[[(2S,5R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,4-dioxan-5-yl]-methylamino]-
1,3,5-triazine (8b). cis-Compound 8b was prepared in 50 % yield from 5b by following the same 
method as for the synthesis of 8a. 1H-NMR (400 MHz, CDCl3) δ 6.34 (t, 1H, J = 6Hz, NH), 5.43 (s, 
4H, NH2), 4.35 (ddd, 1H, J = 6.8Hz, 6.8 Hz, 6.8 Hz, H-8), 4.01 (dd, 1H, J = 8.4 Hz, 6.4 Hz, H-9), 
3.59-3.82 (m, 7H, H-9, H-2, H-3, H-5, H-6), 3.47-3.54 (m, 2H, H-7), 1.43 (s, 3H, H-13), 1.37 (s, 3H, 
H-13) ppm. 13C-NMR (100 MHz, CDCl3) δ  167.5, 167.2, 166.8, 109.9, 74.5, 74.0, 72.1, 65.8, 65.3, 
63.2, 40.0, 26.6, 25.4 ppm. IR (neat) 3342, 3168, 2983, 1539, 1449, 1122, 1065 cm-1. HRMS (m/z, 
ESI): for C13H22N6O4 (M+H+), calcd. 327.1780, found 327.1787. 
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2,4-Dihydroxy-6-[[(2S,5S)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,4-dioxan-5-yl]methylamino]-
1,3,5-triazine (10a). To compound 5a (88 mg, 0.41 mmol) and triethylamine (0.08 mL, 0.58 mmol) in 
DMF (10 mL) was added the monosodium salt of 2-chloro-4,6-dihydroxy-1,3,5-triazine (9, 127 mg, 
0.62 mmol). The mixture was heated at 80 oC and stirred overnight. The solvent was evaporated under 
high vacuum and the residue was purified by flash chromatography using a mixture of 
dichloromethane and methanol (10:1) as eluent. The product 10a (67 mg) was obtained in 43 % yield. 
1H-NMR (400 MHz, CDCl3) δ 10.40 (broad s, 2H, OH), 7.02 (s, 1H, NH), 4.00 (ddd, 1H, J = 6.8 Hz, 
6.8 Hz, 6.8 Hz, H-8), 3.90 (dd, 1H, J = 8.2 Hz, 6.6 Hz, H-9), 3.80 (dd, 1H, J = 11.6 Hz, 2.4 Hz, H-3), 
3.71-3.76 (m, 2H, H-9, H-6), 3.57-3.61 (m, 1H, H-2), 3.46-3.50 (m, 1H, H-5), 3.17-3.44 (m, 4H, H-6, 
H-3, H-7), 1.30 (s, 3H, H-13), 1.24 (s, 3H, H-13) ppm. 13C-NMR (100 MHz, CDCl3) δ 156.5, 108.5, 
74.4 (C-5 and C-8), 72.8, 68.1, 66.7, 64.3, 40.9, 26.1, 25.3 ppm. IR (neat) 3090, 2983, 1720, 1628, 
1490, 1131, 1061 cm-1. HRMS (m/z, ESI), for C13H20N4O6 (M+H+), calcd. 329.1461, found 329.1469. 
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2,4-Dihydroxy-6-[[(2S,5R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,4-dioxan-5-yl]-methylamino]-
1,3,5-triazine (10b). cis-Compound 10b was prepared from 5b by following the same method as for 
the synthesis of 10a. 1H-NMR (400 MHz, CDCl3) δ 10.62 (broad s, 1H, OH), 10.48 (broad s, 1H, OH), 
6.90 (s, 1H, NH), 4.24 (ddd, 1H, J = 6.4 Hz, 6.4 Hz, 6.4 Hz, H-8), 3.94 (dd, 1H, J = 8.4 Hz, 6.8 Hz, H-
9), 3.72 (dd, 1H, J = 8 Hz, 6.8 Hz, H-9), 3.48-3.69 (m, 7H, H-5, H-6, H-3, H-2, H-7), 3.36-3.42 (m, 
1H, H-7), 1.31 (s, 3H, H-13), 1.27 (s, 3H, H-13) ppm. 13C-NMR (100 MHz, CDCl3) δ 156.3, 149.9, 
108.5, 73.8, 73.5, 70.1, 64.8, 64.7, 61.9, 39.3, 26.4, 25.3 ppm. IR (neat) 3126, 2985, 1741, 1588, 1121, 
1060 cm-1. HRMS (m/z, ESI), for C13H20N4O6 (M+H+), calcd. 329.1461, found 329.1462. 
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2-Chloro-4-amino-6-[[(2S,5S)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,4-dioxan-5-yl]-methyl-
amino]-1,3,5-triazine (12a). To compound 5a (40 mg, 0.18 mmol) and triethylamine (0.04 mL, 0.29 
mmol) in DMF (6 mL) was added 2,4-dichloro-6-amino-1,3,5-triazine (11, 31 mg, 0.19 mmol). The 
mixture was stirred at room temperature overnight. The DMF was evaporated under high vacuum and 
the residue was purified by flash chromatography using a mixture of dichloromethane and methanol 
(20:1) as the eluent. The product (53 mg) was obtained in 88 % yield. 1H-NMR (400 MHz, CDCl3, 25 
oC) δ 1.36, 1.43 (s, 2×CH3 for both rotamers), 3.25-3.32 (m), 3.37-3.46 (m), 3.48-3.61 (m), 3.65-3.82 
(m), 3.86-3.93 (m), 4.03-4.08 (m), 5.20-5.40 (broad, 2H, NH2, for both rotamers), 5.83 (t, NH), 6.14 (t, 
NH) ppm. 1H-NMR (400 MHz, CDCl3, 50oC) δ 5.71 (broad s, 1H, NH), 5.19 (broad s, 2H, NH2), 4.03-
4.08 (m, 1H), 3.95 (dd, 8.2, J = 6.6 Hz, 1H), 3.85-3.88 (m, 1H), 3.81 (dd, J = 8.2, J = 7.0 Hz, 1H, ), 
3.74 (dd, J =10.6 and J = 1.4 Hz, 1H), 3.65-3.71 (m, 1H), 3.48-3.60 (m, 3H), 3.40 (dd, J = 11.4 and 
10.6 Hz, 1H), 3.26-3.32 (m, 1H), 1.413, 1.412, 1.342, 1.341 (6H, 2×CH3) ppm. 13C-NMR (100 MHz, 
CDCl3, 50 oC) δ 25.3, 26.3, 41.8, 65.1, 67.5, 68.9, 73.6, 75.1, 75.3, 109.8, 166.5, 167.3, 169.8. IR 
(neat) 3392, 3265, 3119, 2983, 1655, 1576, 1485, 1103, 1056 cm-1. HRMS (m/z, ESI), for 
C13H20ClN5O4 (M+H+), calcd. 346.1282, found 346.1283. 
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2-Chloro-4-amino-6-[[(2S,5R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,4-dioxan-5-yl]-methyl-
amino]-1,3,5-triazine (12b) cis-Compound 12b was prepared by following the same method as for 
synthesis of 12a. 1H-NMR (400 MHz, CDCl3) δ 1.37, 1.44 (s, 2×CH3 for both rotamers), 3.49-
3.55(m), 3.57-3.67(m), 3.75-3.86(m), 3.99-4.06 (m, 1H, for both rotamers), 4.31-4.36 (m, 1H, for both 
rotamers), 5.3-5.9 (broad, 2H, NH2, for both rotamers), 6.02, 6.11 (1H, NH, for both rotamers) ppm. 
13C-NMR (100 MHz, CDCl3) δ 25.2, 25.3, 26.4, 26.5, 62.6, 62.9, 65.4, 65.48, 65.52, 65.6, 70.9, 71.3, 
74.0, 74.4, 166.1, 166.3, 166.6, 167.0, 169.2 ppm. IR (neat) 3327, 3270, 3171, 2983, 1646, 1563, 
1482, 1123, 1065 cm-1. HRMS (m/z, ESI), for C13H20ClN5O4 (M+H+), calcd. 346.1282, found 
346.1295. 
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